These authors contributed equally to this work.
Down expression of LRP1B promotes cell migration via RhoA/Cdc42 pathway and actin cytoskeleton remodeling in renal cell cancer
Article first published online: 16 MAY 2013
© 2013 Japanese Cancer Association
Volume 104, Issue 7, pages 817–825, July 2013
How to Cite
(Cancer Sci 2013; 104: 817–825)
- Issue published online: 24 JUL 2013
- Article first published online: 16 MAY 2013
- Accepted manuscript online: 25 MAR 2013 01:45AM EST
- Manuscript Accepted: 16 MAR 2013
- Manuscript Revised: 11 MAR 2013
- Manuscript Received: 14 OCT 2012
- Heilongjiang Province Research Program. Grant Number: LC04C02
The low-density lipoprotein receptor-related protein 1B (LRP1B) is known as a putative tumor suppressor. The decreased expression of LRP1B has been involved in multiple primary cancers in several studies. However, its expression and function in the carcinogenesis of renal cell cancer (RCC) remain unclear. In this study, we investigated the expression of LRP1B in RCC by in situ hybridization (ISH) and real-time polymerase chain reaction (qRT-PCR). Our results indicated that LRP1B was frequently downexpressed in human RCC tissue and cell lines, which involved both epigenetic events (DNA methylation and histone deacetylation) and N-terminal deletion of LRP1B. Moreover, we testified that knockdown of LRP1B by shRNA significantly promoted anchorage-independent growth, cell migration and invasion in HEK293 cells and renal cancer cells 127 in vitro. We further found that silencing of LRP1B altered the expression of focal adhesion complex-associated proteins, and Cdc42/RhoA activities, which regulate the cytoskeleton dynamics. Taken together, these results strongly support that LRP1B may function as a tumor suppressor against renal cell cancer, and may regulate cell motility via RhoA/Cdc42 pathway and actin cytoskeleton reorganization in RCC.